Anika Therapeutics, Inc. (ANIK) Tops Q1 Revenue Tops Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.58 +0.68%
Revenue Growth %: +5.9%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +5.9%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.97, $0.72 better than the analyst estimate of $0.25. Revenue for the quarter came in at $34 million versus the consensus estimate of $16.03 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plumas Bancorp (PLBC) Tops Q3 EPS by 15c
- TeraWulf shares rise on power demand outlook through 2029
- Morgan Stanley Names Top Aerospace Pick to Replace FTAI
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
